期刊
ACTA PHARMACOLOGICA SINICA
卷 42, 期 12, 页码 1981-1990出版社
NATURE PUBL GROUP
DOI: 10.1038/s41401-021-00616-5
关键词
adenovirus; cervical Cancer; HPV Infection; HPV Oncoproteins; human Papillomavirus; vaccine
Persistent infection with high-risk types of HPV is known to be the leading cause of cervical cancer, leading to the development of various therapeutic approaches, with adenovirus vectors drawing attention due to their strong immunogenicity and safety.
Although most human papillomavirus (HPV) infections are harmless, persistent infection with high-risk types of HPV is known to be the leading cause of cervical cancer. Following the infection of the epithelium and integration into the host genome, the oncogenic proteins E6 and E7 disrupt cell cycle control by inducing p53 and retinoblastoma (Rb) degradation. Despite the FDA approval of prophylactic vaccines, there are still issues with cervical cancer treatment; thus, many therapeutic approaches have been developed to date. Due to strong immunogenicity, a high capacity for packaging foreign DNA, safety, and the ability to infect a myriad of cells, adenoviruses have drawn attention of researchers. Adenovirus vectors have been used for different purposes, including as oncolytic agents to kill cancer cells, carrier for RNA interference to block oncoproteins expression, vaccines for eliciting immune responses, especially in cytotoxic T lymphocytes (CTLs), and gene therapy vehicles for restoring p53 and Rb function.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据